A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors (Q37690991)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors |
scientific article |
Statements
1 reference
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors (English)
1 reference
Clifford Hudis
1 reference
Yelena Y Janjigian
1 reference
Ray Lee
1 reference
Stephanie Sutherland
1 reference
Robert Lehman
1 reference
Sarat Chandarlapaty
1 reference
Nicola Hamilton
1 reference
Devika Gajria
1 reference
James Knowles
1 reference
Jigna Shah
1 reference
Keith Shannon
1 reference
Ernestina Tetteh
1 reference
Daniel M Sullivan
1 reference
Carolina Moreno
1 reference
Li Yan
1 reference
Hyo Sook Han
1 reference
19 November 2013
1 reference
1 reference
R110
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference